| 5 mins | 30 mins | Hourly | Daily | Weekly |
|---|---|---|---|---|
| SELL | SELL | SELL | SELL | SELL |
| 5 mins | 30 mins | Hourly | Daily | Weekly | |
|---|---|---|---|---|---|
| MA5 | 16.07▼ | 16.07▼ | 16.07▼ | 16.93▼ | 21.11▼ |
| MA10 | 16.06▼ | 16.10▼ | 16.08▼ | 19.09▼ | 24.01▼ |
| MA20 | 16.07▼ | 16.13▼ | 16.38▼ | 21.82▼ | 25.11▼ |
| MA50 | 16.10▼ | 17.06▼ | 18.29▼ | 24.73▼ | N/A |
| MA100 | 16.50▼ | 18.95▼ | 21.42▼ | 25.47▼ | N/A |
| MA200 | 17.98▼ | 22.25▼ | 23.86▼ | N/A | N/A |
| 5 mins | 30 mins | Hourly | Daily | Weekly | |
|---|---|---|---|---|---|
| MACD | 0.001▲ | 0.063▲ | 0.107▲ | -0.624▼ | N/A |
| RSI | 39.020▼ | 35.291▼ | 28.613▼ | 23.104▼ | 30.137▼ |
| STOCH | 56.250 | 24.467 | 22.541 | 4.928▼ | 14.419▼ |
| WILL %R | -100.000▼ | -100.000▼ | -98.907▼ | -99.557▼ | -99.715▼ |
| CCI | -177.285▼ | -126.280▼ | -65.293 | -110.707▼ | -232.655▼ |
|
Wednesday, November 12, 2025 05:24 AM
Novo Nordisk's Coramitug cut NT-proBNP levels and was well tolerated in a Phase 2 ATTR-CM trial, paving the way for its Phase 3 CLEOPATTRA study.
|
|
Wednesday, November 12, 2025 04:22 AM
PepGen Inc. (Nasdaq: PEPG), a clinical-stage biotechnology company advancing the next generation of oligonucleotide therapies with the goal of transforming the treatment of severe neuromuscular and ...
|
| date | open | high | low | close | volume |
|---|---|---|---|---|---|
| 14/11/25 | 16.00 | 16.18 | 15.89 | 15.89 | 11,800 |
| 13/11/25 | 16.0775 | 16.39 | 15.845 | 16.39 | 19,876 |
| 12/11/25 | 16.025 | 17.18 | 16.005 | 16.80 | 23,556 |
| 11/11/25 | 18.095 | 18.41 | 17.09 | 17.09 | 22,998 |
| 10/11/25 | 19.24 | 19.24 | 17.87 | 18.455 | 17,064 |
| 07/11/25 | 19.1722 | 19.285 | 18.14 | 18.42 | 23,045 |
| 06/11/25 | 21.57 | 22.925 | 18.69 | 18.95 | 19,340 |
| 05/11/25 | 22.51 | 23.64 | 22.51 | 23.415 | 5,069 |
| 04/11/25 | 22.3184 | 23.23 | 21.6801 | 22.76 | 9,278 |
| 03/11/25 | 20.00 | 23.20 | 19.91 | 22.71 | 20,991 |
|
|
||||
|
|
||||
|
|